Intellia Therapeutics, Inc. - 10-Q Filing
Intellia Therapeutics reports Q3 2026 financial results including new OrbiMed credit facility and ongoing R&D activities.
Tickers: $NTLA
Intellia Therapeutics reports Q3 2026 financial results including new OrbiMed credit facility and ongoing R&D activities.
Tickers: $NTLA